Abstract

BackgroundYTH domain family (YTHDF) 2 acts as a “reader” protein for RNA methylation, which is important in tumor regulation. However, the effect of YTHDF2 in liver hepatocellular carcinoma (LIHC) has yet to be elucidated.MethodsWe explored the role of YTHDF2 in LIHC based on publicly available datasets [The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO)]. A bioinformatics approach was employed to analyze YTHDF2. Logistic regression analyses were applied to analyze the correlation between YTHDF2 expression and clinical characteristics. To evaluate the effect of YTHDF2 on the prognosis of LIHC patients, we used Kaplan–Meier (K–M) curves. Gene set enrichment analysis (GSEA) was undertaken using TCGA dataset. Univariate and multivariate Cox analyses were used to ascertain the correlations between YTHDF2 expression and clinicopathologic characteristics with survival. Genes co-expressed with YTHDF2 were identified and detected using publicly available datasets [LinkedOmics, University of California, Santa Cruz (UCSC), Gene Expression Profiling Interactive Analysis (GEPIA), and GEO]. Correlations between YTHDF2 and infiltration of immune cells were investigated by Tumor Immune Estimation Resource (TIMER) and GEPIA.ResultsmRNA and protein expression of YTHDF2 was significantly higher in LIHC tissues than in non-cancerous tissues. High YTHDF2 expression in LIHC was associated with poor prognostic clinical factors (high stage, grade, and T classification). K–M analyses indicated that high YTHDF2 expression was correlated with an unfavorable prognosis. Univariate and multivariate Cox analyses revealed that YTHDF2 was an independent factor for a poor prognosis in LIHC patients. GSEA revealed that the high-expression phenotype of YTHDF2 was consistent with the molecular pathways implicated in LIHC carcinogenesis. Analyses of receiver operating characteristic curves showed that YTHDF2 might have a diagnostic value in LIHC patients. YTHDF2 expression was associated positively with SF3A3 expression, which implied that they may cooperate in LIHC progression. YTHDF2 expression was associated with infiltration of immune cells and their marker genes. YTHDF2 had the potential to regulate polarization of tumor-associated macrophages, induce T-cell exhaustion, and activate T-regulatory cells.ConclusionYTHDF2 may be a promising biomarker for the diagnosis and prognosis of LIHC and may provide new directions and strategies for LIHC treatment.

Highlights

  • Liver cancer is one of the deadliest types of cancer

  • Clinical-feature data and mRNA-expression data of liver hepatocellular carcinoma (LIHC) patients were captured from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases on June 2019 (Supplementary Table 1)

  • We focused on the relationship between YTHDF2 and marker genes of various types of immune cells [CD8+ T cells, monocytes, T cells, M1 and M2 macrophages, B cells, neutrophils, tumor-associated macrophages (TAMs), natural killer cells, AND dendritic cells (DCs)] in LIHC in Gene Expression Profiling Interactive Analysis (GEPIA) and Tumor Immune Estimation Resource (TIMER) databases

Read more

Summary

Introduction

About 90% of primary liver cancers are liver hepatocellular carcinoma (LIHC). The latter results in >700,000 deaths and 850,000 new cases annually globally and is the fifth most prevalent cancer type worldwide (Tomita et al, 2011; Torre et al, 2015; Llovet et al, 2016). LIHC remains a major challenge of treatment due to its high morbidity and mortality, lack of effective diagnosis and treatment, and extremely poor prognosis (Mittal and El-Serag, 2013). There is a lack of effective biomarkers to predict the prognosis. Discovering reliable prognostic biomarkers for LIHC is very important. The effect of YTHDF2 in liver hepatocellular carcinoma (LIHC) has yet to be elucidated

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call